Population Diagnostics, Melville, NY, recently announced that it is changing its corporate name to Population Bio. According to the company, the name change reflects both its broader commitment to precision medicine and its expertise in driving the innovations needed to shape the future of drug development and predictive diagnostics. The new name is effective immediately.
Jim Chinitz, Population Bio.
“The new name, Population Bio, better reflects our corporate mission of uncovering new truths and insights about health and disease that are the key to winning the race in precision medicine,” says Jim Chinitz, CEO of Population Bio. “As a company with its roots in genomic technology, we are committed to delivering breakthroughs that will be at the heart of the next generation of therapeutics and diagnostics.”
Addressing critical health concerns, the company’s patented technology is currently in clinical studies, collaborations, and partnerships addressing such complex neurological diseases as Alzheimer’s, autism, Parkinson’s, and progressive multifocal leukoencephalopathy, in addition to other common conditions having a genetic component, such as endometriosis and peanut allergy.
For more information, visit Population Bio.
